We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Elderly Subjects Supplemented with L-Glutamine Shows an Improvement of Mucosal Immunity in the Upper Airways in Response to Influenza Virus Vaccination.
- Authors
Paixão, Vitória; Almeida, Ewin B.; Amaral, Jonatas B.; Roseira, Tamaris; Monteiro, Fernanda R.; Foster, Roberta; Sperandio, Adriane; Rossi, Marcelo; Amirato, Gislene R.; Santos, Carlos A. F.; Pires, Renier S.; Leal, Fabyano B.; Durigon, Edison L.; Oliveira, Danielle B. L.; Vieira, Rodolfo P.; Vaisberg, Mauro; Santos, Juliana M. B.; Bachi, André L. L.; Furuya, Yoichi; Wijesundara, Danushka
- Abstract
Background: Although glutamine is able to improve the immune response, its action in the upper airway immunity against the influenza virus vaccine remains unclear. Therefore, we aimed to evaluate the L-glutamine supplementation effect on the mucosal immune/inflammatory response of elderly subjects vaccinated against the influenza virus. Methods: Saliva sampling from 83 physically active elderly volunteers were collected pre- and 30 days after influenza virus vaccination and supplementation with L-glutamine (Gln, n = 42) or placebo (PL, n = 41). Results: Gln group showed higher salivary levels of interleukin (IL)-17, total secretory immunoglobulin A (SIgA), and specific-SIgA post-vaccination than values found pre-vaccination and in the PL group post-vaccination. Whereas higher salivary levels of IL-6 and IL-10 were observed post-vaccination in the Gln group, IL-37 levels were lower post-vaccination in both groups than the values pre-vaccination. Tumor necrosis factor (TNF)-α levels were unchanged. Positive correlations between IL-6 and IL-10 were found in all volunteer groups pre- and post-vaccination and also between IL-17 and IL-6 or IL-10 in the Gln group post-vaccination. A negative correlation between IL-37 and IL-10 was found pre- and post-vaccination in the PL group. Conclusion: Gln supplementation was able to modulate salivary cytokine profile and increase SIgA levels, both total and specific to the influenza virus vaccine, in physically active elderly subjects.
- Subjects
INFLUENZA A virus; INFLUENZA vaccines; TUMOR necrosis factors; OLDER people; IMMUNITY
- Publication
Vaccines, 2021, Vol 9, Issue 2, p107
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines9020107